BR0011823A - Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo - Google Patents

Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo

Info

Publication number
BR0011823A
BR0011823A BR0011823-0A BR0011823A BR0011823A BR 0011823 A BR0011823 A BR 0011823A BR 0011823 A BR0011823 A BR 0011823A BR 0011823 A BR0011823 A BR 0011823A
Authority
BR
Brazil
Prior art keywords
benzimidazole derivative
relieving
disorder
disease
treating
Prior art date
Application number
BR0011823-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Lene Teuber
Frank Wotjen
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of BR0011823A publication Critical patent/BR0011823A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR0011823-0A 1999-06-22 2000-06-22 Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo BR0011823A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900888 1999-06-22
PCT/DK2000/000333 WO2000078728A1 (en) 1999-06-22 2000-06-22 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds

Publications (1)

Publication Number Publication Date
BR0011823A true BR0011823A (pt) 2002-03-19

Family

ID=8098669

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011823-0A BR0011823A (pt) 1999-06-22 2000-06-22 Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo

Country Status (14)

Country Link
US (2) US6649609B2 (enExample)
EP (1) EP1194410B1 (enExample)
JP (1) JP2003502405A (enExample)
CN (1) CN1167686C (enExample)
AT (1) ATE316076T1 (enExample)
AU (1) AU777961B2 (enExample)
BR (1) BR0011823A (enExample)
CA (1) CA2373921A1 (enExample)
DE (1) DE60025604T2 (enExample)
IL (2) IL146403A0 (enExample)
MX (1) MXPA02000107A (enExample)
NZ (1) NZ515543A (enExample)
RU (1) RU2243226C2 (enExample)
WO (1) WO2000078728A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
JP2003502405A (ja) * 1999-06-22 2003-01-21 ニューロサーチ、アクティーゼルスカブ 新規ベンズイミダゾール誘導体及びこれらの化合物を含有する薬学的に容認された塩
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
GB0117277D0 (en) * 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
DE60115282T2 (de) * 2000-11-10 2006-08-10 Merck Sharp & Dohme Ltd., Hoddesdon Imidazotriazin-derivate als liganden für gaba-rezeptoren
WO2002050057A1 (en) * 2000-12-20 2002-06-27 Neurosearch A/S Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
US6743796B2 (en) * 2001-05-07 2004-06-01 Wyeth Piperazinyl-isatins
AUPR625901A0 (en) * 2001-07-10 2001-08-02 Mcgregor, Neil A method for treatment and/or prophylaxis
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
JP2006522069A (ja) 2003-04-03 2006-09-28 ニューロサーチ、アクティーゼルスカブ ベンズイミダゾール誘導体及びこれをgabaa受容体複合体をモジュレートするために使用する方法
NZ541544A (en) 2003-04-03 2008-06-30 Neurosearch As Benzimidazole derivatives and their use for modulating the GABAA receptor complex
EP1615896B1 (en) * 2003-04-10 2008-04-23 Neurosearch A/S Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
EP1678144A1 (en) * 2003-10-23 2006-07-12 Akzo Nobel N.V. 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-a RECEPTOR COMPLEX
NZ547109A (en) 2003-10-28 2010-03-26 Vertex Pharma Benzimidazoles useful as modulators of ion channels
ZA200603165B (en) * 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US20060185357A1 (en) * 2004-05-07 2006-08-24 Kovacevich Ian D Independently drawing and tensioning lines with bi-directional rotary device having two spools
MXPA06013944A (es) 2004-06-08 2007-10-08 Neurosearch Sweden Ab Nuevas fenilpiperidinas/piperazinas disustituidas como moduladores de la neurotransmision de dopamina.
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
BRPI0606110A2 (pt) 2005-01-25 2009-06-02 Epix Delaware Inc compostos de arilamina substituìdos e seu uso como 5 - ht6 moduladores
WO2006108800A1 (en) * 2005-04-13 2006-10-19 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
US20090062304A1 (en) * 2005-04-19 2009-03-05 Lene Teuber Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex
WO2006111516A1 (en) * 2005-04-19 2006-10-26 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
EP1874735A1 (en) * 2005-04-19 2008-01-09 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US7858649B2 (en) 2005-10-14 2010-12-28 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
WO2007042545A1 (en) * 2005-10-14 2007-04-19 Neurosearch A/S Imidazole derivatives and their use for modulating the gaba-a receptor complex
CA2632395A1 (en) * 2005-12-05 2007-06-14 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
TWI391381B (zh) * 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
JP5443342B2 (ja) 2007-06-08 2014-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピペリジン/ピペラジン誘導体
AU2008258487B2 (en) * 2007-06-08 2012-11-15 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JP5464709B2 (ja) * 2007-06-08 2014-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピペリジン/ピペラジン誘導体
ES2617619T3 (es) * 2008-06-05 2017-06-19 Janssen Pharmaceutica, N.V. Combinaciones de fármacos que comprenden un inhibidor de DGAT y un agonista de PPAR
CN102206204B (zh) * 2011-04-08 2012-12-12 奇方(天津)医药科技有限公司 一种苯并咪唑类化合物及其医药用途
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH 併用療法のための医薬組成物
KR20200023034A (ko) * 2018-08-24 2020-03-04 일양약품주식회사 이속사졸 유도체 및 그의 제조방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788751A (fr) * 1971-09-13 1973-01-02 Teijin Ltd Membranes polymeres permselectives
US5149814A (en) * 1987-09-30 1992-09-22 Pfizer Inc Alkyl 2-benzylidene-4-(2-alkylimidazopyrid-1-yl) benzoylacetate esters as intermediate compounds
ZA90673B (en) * 1989-02-02 1990-10-31 Yamanouchi Pharma Co Ltd Tetrahydrobenzimidazole derivatives
DE3928177A1 (de) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH05507469A (ja) * 1990-04-13 1993-10-28 スミスクライン・ビーチャム・コーポレイション 置換ベンズイミダゾール
US6034114A (en) * 1990-12-14 2000-03-07 Smithkline Beecham Plc Medicament
DK40192D0 (da) * 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
DE4237656A1 (de) * 1992-06-13 1993-12-16 Merck Patent Gmbh Benzimidazolderivate
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
US5554630A (en) * 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
JP3342874B2 (ja) * 1995-04-21 2002-11-11 ニューロサーチ、アクティーゼルスカブ ベンズイミダゾール化合物、およびgabaaレセプター複合体モジュレーターとしてのその使用
AU699623B2 (en) * 1995-04-21 1998-12-10 Neurosearch A/S Benzimidazole compounds and their use as modulators of the GABAA receptor complex
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
WO1998017651A1 (en) * 1996-10-21 1998-04-30 Neurosearch A/S 1-phenyl-benzimidazole compounds and their use as baga-a receptor modulators
FR2755364B1 (fr) * 1996-11-06 1999-01-22 Eugene Perma Sa Composition pour la deformation permanente des fibres keratiniques, obtention et mise en oeuvre
GB9702524D0 (en) * 1997-02-07 1997-03-26 Merck Sharp & Dohme Therapeutic agents
NZ503435A (en) * 1997-10-10 2001-12-21 Neurosearch As Oxime substituted 1-(3-(heteroaryl)phenyl)-benzimidazole compounds having GABA activity
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
JP2003502405A (ja) * 1999-06-22 2003-01-21 ニューロサーチ、アクティーゼルスカブ 新規ベンズイミダゾール誘導体及びこれらの化合物を含有する薬学的に容認された塩
DE10060292A1 (de) * 2000-12-05 2002-06-20 Aventis Pharma Gmbh Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament

Also Published As

Publication number Publication date
EP1194410A1 (en) 2002-04-10
EP1194410B1 (en) 2006-01-18
US6649609B2 (en) 2003-11-18
DE60025604D1 (de) 2006-04-06
AU5391000A (en) 2001-01-09
US6936613B2 (en) 2005-08-30
CA2373921A1 (en) 2000-12-28
IL146403A (en) 2007-08-19
US20040097570A1 (en) 2004-05-20
US20030055055A1 (en) 2003-03-20
AU777961B2 (en) 2004-11-04
IL146403A0 (en) 2002-07-25
ATE316076T1 (de) 2006-02-15
NZ515543A (en) 2003-11-28
CN1167686C (zh) 2004-09-22
RU2243226C2 (ru) 2004-12-27
CN1356987A (zh) 2002-07-03
MXPA02000107A (es) 2002-07-02
DE60025604T2 (de) 2006-07-27
JP2003502405A (ja) 2003-01-21
WO2000078728A1 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
BR0011823A (pt) Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo
Park et al. Human adipose tissue‐derived mesenchymal stem cells improve cognitive function and physical activity in ageing mice
Gong et al. Dopamine D1/D2 agonists injected into nucleus accumbens and ventral pallidum differentially affect locomotor activity depending on site
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR0013366A (pt) Métodos para tratar um distúrbio comportamental, um paciente humano, doença de próstata, distúrbios de ansiedade e cognitivos em um paciente humano afligido com uma condição ou disposto ao desenvolvimento de uma condição distinguida pelo menos em parte pela concentração de glutamato extracelular anormal no cérebro ou em outro tecido nervoso, distúrbio comportamental nas espécies humana, canina, felina e equina e um paciente afligido com ou disposto a desenvolver uma doença compreendendo concentrações de glutamato anormalmente elevadas em tecido neuronal ou nìveis de naaladase elevados em tecido prostático e com esclerose múltipla e para realçar a função cognitiva, formulação farmacêutica e usos de um inibidor da atividade de peptidase de uma dipeptidase ácida ligada em alfa n-acetilada e de um composto de beta-lactama
BRPI0416212A (pt) derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação
UY30686A1 (es) "receptor nicotinico de acetilcolina, subtipo selectivo de amidas de diazabiciloalcanos"
DK1632483T3 (da) Heterocykliske, substituerede carbonylderivater og deres anvendelse som dopamin-D3-receptorligander
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
AR029025A1 (es) Derivados de adenosina n6 heterociclicos 5' modificados, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de un medicamento
Singla et al. Comparison of dexmedetomidine versus midazolam for intranasal premedication in children posted for elective surgery: a double-blind, randomised study
Müller et al. Effect of butorphanol, midazolam or ketamine on romifidine based sedation in horses during standing cheek tooth removal
Reiss et al. Chronic activity wheel running reduces the severity of kainic acid-induced seizures in the rat: possible role of galanin
BRPI0409796A (pt) uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
Woodlee et al. The interplay between behavior and neurodegeneration in rat models of Parkinson's disease and stroke
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BRPI0507296A (pt) derivado de uréia, composição farmacêutica, uso de um derivado de uréia, e, método de tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou uma condição de um corpo de animal vivo
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
Sinopoulou et al. Chronic muscle recordings reveal recovery of forelimb function in spinal injured female rats after cortical epidural stimulation combined with rehabilitation and chondroitinase ABC
Safari et al. Effect of lidocaine administration at the nucleus locus coeruleus level on lateral hypothalamus-induced antinociception in the rat
EA200800397A1 (ru) Композиции тизанидина и способы лечения с применением композиций
Radiloff et al. Anti-hypotensive treatment and endothelin blockade synergistically antagonize exercise fatigue in rats under simulated high altitude
Zhang et al. Effects of neonatal inflammation on descending modulation from the rostroventromedial medulla

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements